2023 New Drug Approvals: Part 3
In part 3 of this slideshow series, take a look back at the novel drugs and therapeutics approved by the FDA in 2023,1 including treatments for large B-cell lymphoma, respiratory syncytial virus (RSV), and acute myeloid leukemia (AML).
References
1. Novel drug approvals for 2023. FDA. Reviewed November 28, 2023. Accessed November 28, 2023. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023
2. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas. FDA. June 16, 2023. Accessed November 28, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell
3. FDA approves Pfizer’s Litfulo (ritlecitinib) for adults and adolescents with severe alopecia areata. News release. Pfizer. June 23, 2023. Accessed November 28, 2023. https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and
4. UCB announces US FDA approval of Rystiggo (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis. News release. UCB. June 28, 2023. Accessed November 28, 2023. https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-US-FDA-approval-of-RYSTIGGOR-rozanolixizumab-noli-for-the-treatment-of-adults-with-generalized-myasthenia-gravis
5. FDA approves Pfizer’s Ngenla, a long-acting once-weekly treatment for pediatric growth hormone deficiency. June 28, 2023. Accessed November 28, 2023. https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-ngenlatm-long-acting-once-weekly
6. FDA approves new drug to prevent RSV in babies and toddlers. News release. FDA. July 17, 2023. Accessed November 28, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers
7. FDA approves quizartinib for newly diagnosed acute myeloid leukemia. FDA. July 20, 2023. Accessed November 28, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia
8. FDA approves Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. News release. Tarsus Pharmaceuticals. July 25, 2023. Accessed November 28, 2023. https://ir.tarsusrx.com/news-releases/news-release-details/fda-approves-xdemvytm-lotilaner-ophthalmic-solution-025
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Recent Videos
Related Content
Improved Understanding of Hidradenitis Suppurativa Can Enhance Patient Outcomes
July 14th 2025Article
Researchers assessed the difference between hidradenitis suppurativa and other skin conditions regarding the initiating events, inflammatory signature, and molecular and clinical features of each disease.
